MGNX
Macrogenics Inc
A biotech company that engineers antibody-based therapies to fight cancer. Its drug MARGENZA was approved in 2020 for HER2-positive breast cancer, and its DART platform builds proteins that bind two targets at once, steering immune cells toward tumors. Founded in 2000 in Rockville, Maryland, by a team of scientists, its name combines "macro," for the large protein molecules it builds, with "genics," echoing genetic engineering.
CUSIP: 556099109HealthcareUS1 holder
Recent Activity
2017Q1
1 sell
-175.0K shares
-175.0K shares
Loading more activity...